Leerink Swann Begins Coverage on GENFIT S A/ADR (GNFT)

Leerink Swann assumed coverage on shares of GENFIT S A/ADR (NASDAQ:GNFT) in a report published on Wednesday, April 24th, The Fly reports. The firm issued an outperform rating and a $25.47 target price on the stock.

Other equities research analysts also recently issued research reports about the company. HC Wainwright decreased their target price on GENFIT S A/ADR to $72.00 and set a buy rating for the company in a report on Monday, April 22nd. Barclays began coverage on GENFIT S A/ADR in a report on Monday, April 22nd. They set an overweight rating and a $55.00 target price for the company. Five equities research analysts have rated the stock with a buy rating, GENFIT S A/ADR has a consensus rating of Buy and an average target price of $52.62.

GNFT traded down $0.32 on Wednesday, hitting $23.55. The company had a trading volume of 30,500 shares, compared to its average volume of 158,319. GENFIT S A/ADR has a 12-month low of $20.81 and a 12-month high of $26.25.

A number of large investors have recently made changes to their positions in GNFT. Morgan Stanley acquired a new position in GENFIT S A/ADR in the first quarter valued at approximately $206,000. BlueCrest Capital Management Ltd purchased a new stake in shares of GENFIT S A/ADR in the first quarter valued at approximately $240,000. New York State Common Retirement Fund purchased a new stake in shares of GENFIT S A/ADR in the first quarter valued at approximately $267,000. One68 Global Capital LLC purchased a new stake in shares of GENFIT S A/ADR in the first quarter valued at approximately $270,000. Finally, Schonfeld Strategic Advisors LLC purchased a new stake in shares of GENFIT S A/ADR in the first quarter valued at approximately $449,000. 1.04% of the stock is owned by institutional investors.

GENFIT S A/ADR Company Profile

Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis.

Featured Article: Average Daily Trade Volume – What It Means In Stock Trading

The Fly

Analyst Recommendations for GENFIT S A/ADR (NASDAQ:GNFT)

Receive News & Ratings for GENFIT S A/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENFIT S A/ADR and related companies with MarketBeat.com's FREE daily email newsletter.